GTX Corp Announces Presentation on the Ability of Capesaris® to Reduce Free Testosterone and Suppress PSA in Men With Castration Resistant Prostate Cancer  
9/19/2012 8:49:19 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today there will be a presentation on the mechanism of action of Capesaris® to induce sex hormone binding globulin (SHBG) and subsequently reduce free testosterone (FT) in men with castration resistant prostate cancer. On September 29, 2012, between 1:00 and 2:00pm Vienna time, at the European Society for Medical Oncology (ESMO) 2012 to be held in Vienna, Austria from September 28 through October 2, 2012, GTx will make a presentation entitled: “GTx-758, an Oral ERa Agonist, Increases Sex Hormone Binding Globulin, Reduces Free T and Decreases PSA in Patients With Castration Resistant Prostate Cancer.”